MA56508A - Inhibiteur d'egfr pour le traitement du cancer - Google Patents

Inhibiteur d'egfr pour le traitement du cancer

Info

Publication number
MA56508A
MA56508A MA056508A MA56508A MA56508A MA 56508 A MA56508 A MA 56508A MA 056508 A MA056508 A MA 056508A MA 56508 A MA56508 A MA 56508A MA 56508 A MA56508 A MA 56508A
Authority
MA
Morocco
Prior art keywords
cancer
treatment
egfr inhibitor
egfr
inhibitor
Prior art date
Application number
MA056508A
Other languages
English (en)
Other versions
MA56508B1 (fr
Inventor
Cosimo Dolente
Annick Goergler
David Hewings
Georg Jaeschke
Bernd Kuhn
Yvonne Alice Nagel
Sander Ulrike Obst
Antonio Ricci
Daniel Rueher
Sandra Steiner
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA56508A publication Critical patent/MA56508A/fr
Publication of MA56508B1 publication Critical patent/MA56508B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA56508A 2019-06-21 2020-06-19 Inhibiteur de l'egfr pour le traitement du cancer MA56508B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19181754 2019-06-21
PCT/EP2020/067076 WO2020254562A1 (fr) 2019-06-21 2020-06-19 Inhibiteur d'egfr pour le traitement du cancer

Publications (2)

Publication Number Publication Date
MA56508A true MA56508A (fr) 2022-04-27
MA56508B1 MA56508B1 (fr) 2023-11-30

Family

ID=67139601

Family Applications (1)

Application Number Title Priority Date Filing Date
MA56508A MA56508B1 (fr) 2019-06-21 2020-06-19 Inhibiteur de l'egfr pour le traitement du cancer

Country Status (31)

Country Link
US (5) US12479849B2 (fr)
EP (4) EP3986896B1 (fr)
JP (4) JP7550800B2 (fr)
KR (1) KR102913816B1 (fr)
CN (4) CN113993872B (fr)
AR (4) AR119209A1 (fr)
AU (1) AU2020295703B2 (fr)
BR (1) BR112021025445B1 (fr)
CA (1) CA3140485A1 (fr)
CL (1) CL2021003408A1 (fr)
CO (1) CO2021017173A2 (fr)
CR (1) CR20210624A (fr)
DK (1) DK3986897T3 (fr)
ES (1) ES2961187T3 (fr)
FI (1) FI3986897T3 (fr)
HR (1) HRP20231276T1 (fr)
HU (1) HUE063676T2 (fr)
IL (1) IL288522B2 (fr)
LT (1) LT3986897T (fr)
MA (1) MA56508B1 (fr)
MX (1) MX2021015464A (fr)
MY (1) MY209340A (fr)
PE (1) PE20220576A1 (fr)
PH (1) PH12021553190A1 (fr)
PL (1) PL3986897T3 (fr)
PT (1) PT3986897T (fr)
RS (1) RS64720B1 (fr)
SI (1) SI3986897T1 (fr)
TW (4) TW202115072A (fr)
UA (1) UA129328C2 (fr)
WO (4) WO2020254572A1 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202115073A (zh) * 2019-06-21 2021-04-16 瑞士商赫孚孟拉羅股份公司 新穎的egfr抑制劑
ES2961187T3 (es) 2019-06-21 2024-03-08 Hoffmann La Roche Inhibidor de EGFR para el tratamiento del cáncer
AU2020383423B2 (en) 2019-11-11 2026-06-18 Dana-Farber Cancer Institute, Inc. Allosteric EGFR inhibitors and methods of use thereof
IL303064A (en) 2020-12-01 2023-07-01 Hoffmann La Roche NEW INDAZOLE ACETYLENE DERIVATIVES
JP7798887B2 (ja) * 2020-12-01 2026-01-14 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 新規インダゾール誘導体
CN116507328A (zh) 2020-12-01 2023-07-28 豪夫迈·罗氏有限公司 新的吲唑衍生物
CN117440813A (zh) * 2021-05-26 2024-01-23 C4医药公司 治疗脑或cns的癌转移的egfr降解剂
BR112023024507A2 (pt) * 2021-05-26 2024-02-15 C4 Therapeutics Inc Método para tratar um câncer mediado por receptor do fator de crescimento epidérmico mutante que sofreu metástase para o cérebro ou sistema nervoso central
EP4522113A1 (fr) * 2022-05-13 2025-03-19 F. Hoffmann-La Roche AG Combinaison d'inhibiteurs allostériques et orthopédiques de l'egfr pour le traitement du cancer
JP2025515833A (ja) * 2022-05-13 2025-05-20 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 新規インダゾール誘導体
CN121487738A (zh) 2023-03-30 2026-02-06 锐新医药公司 诱导ras gtp水解的组合物和其用途
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (fr) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Inhibiteurs de ras
WO2025240847A1 (fr) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Inhibiteurs de ras
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (fr) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Compositions thérapeutiques et procédés de gestion d'effets liés au traitement
WO2026006747A1 (fr) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026015790A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026015801A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble liés à ras
WO2026015825A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Utilisation d'un inhibiteur de ras pour traiter le cancer du pancréas
WO2026015796A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026050446A1 (fr) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026072904A2 (fr) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions et méthodes de traitement du cancer du poumon
WO2026090116A2 (fr) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Inhibiteurs de ras
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (fr) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Utilisation d'inhibiteurs ras pour traiter un cancer
WO2026106912A1 (fr) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026112260A1 (fr) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026122764A2 (fr) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026128688A2 (fr) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026161839A1 (fr) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Inhibiteurs de ras

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0508715D0 (en) * 2005-04-29 2005-06-08 Astrazeneca Ab Chemical compounds
CN101273033A (zh) * 2005-09-20 2008-09-24 阿斯利康(瑞典)有限公司 作为治疗癌症的erbb受体酪氨酸激酶抑制剂的4-（1h-吲哚-5-基-氨基）-喹唑啉化合物
US20110212078A1 (en) 2008-06-25 2011-09-01 Reddy Panduranga Adulla P Synthesis and use of heterocyclic antibacterial agents
US8420661B2 (en) 2010-04-13 2013-04-16 Hoffmann-La Roche Inc. Arylethynyl derivatives
LT2964638T (lt) 2013-03-06 2017-12-27 Astrazeneca Ab Epidermio augimo faktoriaus receptoriaus aktyvinančių mutacijų formų chinazolino inhibitoriai
WO2015095807A1 (fr) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Traitements du cancer au moyen de combinaisons d'inhibiteurs de l'egfr et de l'erk
CN105777756B (zh) * 2014-07-02 2019-03-01 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
JP6639497B2 (ja) * 2014-11-10 2020-02-05 ジェネンテック， インコーポレイテッド ブロモドメインインヒビターおよびその使用
KR102616818B1 (ko) 2015-05-14 2023-12-22 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 Ebna1 억제제 및 그의 사용 방법
HK1252693A1 (zh) 2015-06-30 2019-05-31 Dana Farber Cancer Institute, Inc. Egfr抑制剂及其使用方法
TW201834651A (zh) 2016-12-22 2018-10-01 瑞士商赫孚孟拉羅股份公司 化合物
ES2927480T3 (es) 2017-06-02 2022-11-07 Hoffmann La Roche Compuestos de isoindolina-acetileno para el tratamiento del cáncer
WO2018220149A1 (fr) * 2017-06-02 2018-12-06 F. Hoffmann-La Roche Ag Composés
WO2019046668A1 (fr) * 2017-08-31 2019-03-07 Kezar Life Sciences Thiazoles à substitution amide utilisés en tant qu'inhibiteurs de la sécrétine protéique
IL279800B2 (en) 2018-06-29 2024-02-01 Hoffmann La Roche Selective allosteric inhibitors of epidermal growth factor receptor mutants, pharmaceutical preparations containing them and their use
ES2961187T3 (es) 2019-06-21 2024-03-08 Hoffmann La Roche Inhibidor de EGFR para el tratamiento del cáncer
US20220315577A1 (en) 2019-06-21 2022-10-06 Hoffmann-La Roche Inc. New egfr inhibitors
TW202115073A (zh) 2019-06-21 2021-04-16 瑞士商赫孚孟拉羅股份公司 新穎的egfr抑制劑
AR120800A1 (es) 2019-12-20 2022-03-16 Hoffmann La Roche Derivados de 6,7-dihidro-5h-pirrolo[1,2-c]imidazol como inhibidores de egfr
AR120799A1 (es) 2019-12-20 2022-03-16 Hoffmann La Roche 2-[4-cloro-6-[2-[4-[[4-(hidroximetil)-1-piperidil]metil]fenil]etinil]-1-oxoisoindolin-2-il]-2-(6,7-dihidro-5h-pirrolo[1,2-c]imidazol-1-il)-n-tiazol-2-il-acetamida como inhibidor de egfr
CN116507328A (zh) 2020-12-01 2023-07-28 豪夫迈·罗氏有限公司 新的吲唑衍生物
JP7798887B2 (ja) 2020-12-01 2026-01-14 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 新規インダゾール誘導体
IL303064A (en) 2020-12-01 2023-07-01 Hoffmann La Roche NEW INDAZOLE ACETYLENE DERIVATIVES
JP2025515833A (ja) 2022-05-13 2025-05-20 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 新規インダゾール誘導体
EP4522113A1 (fr) 2022-05-13 2025-03-19 F. Hoffmann-La Roche AG Combinaison d'inhibiteurs allostériques et orthopédiques de l'egfr pour le traitement du cancer

Also Published As

Publication number Publication date
US20230054473A1 (en) 2023-02-23
CN113993872B (zh) 2024-09-24
RS64720B1 (sr) 2023-11-30
TW202115071A (zh) 2021-04-16
CN113993872A (zh) 2022-01-28
US20250289824A1 (en) 2025-09-18
PH12021553190A1 (en) 2022-11-07
AU2020295703B2 (en) 2026-02-12
CR20210624A (es) 2022-02-14
JP2022538403A (ja) 2022-09-02
EP3986898A1 (fr) 2022-04-27
KR102913816B1 (ko) 2026-01-16
TW202115074A (zh) 2021-04-16
EP3986898B1 (fr) 2023-03-15
JP7530391B2 (ja) 2024-08-07
CN114008049B (zh) 2024-07-05
EP3986896B1 (fr) 2023-03-15
JP2022537769A (ja) 2022-08-29
MX2021015464A (es) 2022-01-24
EP3986895B1 (fr) 2023-03-15
JP7550800B2 (ja) 2024-09-13
BR112021025445A2 (pt) 2022-02-01
WO2020254572A1 (fr) 2020-12-24
CA3140485A1 (fr) 2020-12-24
US20220315592A1 (en) 2022-10-06
KR20220024105A (ko) 2022-03-03
CN113993873A (zh) 2022-01-28
TW202115072A (zh) 2021-04-16
CO2021017173A2 (es) 2022-01-17
AR119208A1 (es) 2021-12-01
HRP20231276T1 (hr) 2024-02-02
WO2020254562A1 (fr) 2020-12-24
WO2020254565A1 (fr) 2020-12-24
TW202115053A (zh) 2021-04-16
US12479849B2 (en) 2025-11-25
CN113993873B (zh) 2024-08-02
US20220315593A1 (en) 2022-10-06
EP3986896A1 (fr) 2022-04-27
AR119210A1 (es) 2021-12-01
JP7550798B2 (ja) 2024-09-13
LT3986897T (lt) 2023-11-10
IL288522A (en) 2022-01-01
SI3986897T1 (sl) 2023-12-29
CN114008049A (zh) 2022-02-01
US20220135571A1 (en) 2022-05-05
CN113966335A (zh) 2022-01-21
IL288522B2 (en) 2025-02-01
AR119206A1 (es) 2021-12-01
JP2022538055A (ja) 2022-08-31
CL2021003408A1 (es) 2022-10-14
UA129328C2 (uk) 2025-03-19
JP7550799B2 (ja) 2024-09-13
DK3986897T3 (da) 2023-10-30
EP3986895A1 (fr) 2022-04-27
AR119209A1 (es) 2021-12-01
JP2022537191A (ja) 2022-08-24
TWI869416B (zh) 2025-01-11
CN113966335B (zh) 2024-08-02
MY209340A (en) 2025-07-03
FI3986897T3 (fi) 2023-10-20
PE20220576A1 (es) 2022-04-20
AU2020295703A1 (en) 2022-01-06
BR112021025445B1 (pt) 2024-02-27
MA56508B1 (fr) 2023-11-30
ES2961187T3 (es) 2024-03-08
US12344613B2 (en) 2025-07-01
WO2020254568A1 (fr) 2020-12-24
EP3986897A1 (fr) 2022-04-27
HUE063676T2 (hu) 2024-01-28
PT3986897T (pt) 2023-10-23
EP3986897B1 (fr) 2023-08-30
IL288522B1 (en) 2024-10-01
PL3986897T3 (pl) 2024-01-22

Similar Documents

Publication Publication Date Title
MA55959A (fr) Dosage d'inhibiteur de kras pour le traitement de cancers
EP3947715A4 (fr) Procédés et compositions pour le traitement du cancer
EP3894392A4 (fr) Compositions et procédés pour le traitement du cancer
EP3959218A4 (fr) Promédicaments d'un inhibiteur de cdk pour le traitement de cancers
EP3641829A4 (fr) Promédicament d'interféron pour le traitement du cancer
EP3867410A4 (fr) Procédés de détermination d'un traitement pour des patients atteints d'un cancer
MA56050A (fr) Inhibiteurs hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer
MA52780A (fr) Inhibiteurs de kras g12c pour le traitement du cancer
MA54608A (fr) Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer
MA52564A (fr) Inhibiteurs de kras g12c pour le traitement du cancer
IL288522A (en) Inhibitor of egfr for cancer treatment
EP3908601A4 (fr) Procédés et compositions pour le traitement du cancer
EP3790867A4 (fr) Inhibiteurs de kdm1a pour le traitement d'une maladie
EP3947460A4 (fr) Agents multispécifiques pour le traitement du cancer
EP3630080A4 (fr) Utilisation d'inhibiteurs de ezh2 pour le traitement du cancer
EP4229048A4 (fr) Acylsulfonamides substitués pour le traitement du cancer
EP4259147A4 (fr) Polythérapies pour le traitement du cancer
MA55093A (fr) Méthodes et compositions pour le traitement du cancer
EP4319750A4 (fr) Polythérapies pour le traitement du cancer
EP3793544A4 (fr) Compositions bifonctionnelles pour le traitement du cancer
EP3877402A4 (fr) Traitement combiné pour l'hypertension résistante
MA51613A (fr) Polythérapie pour le traitement ou la prévention du cancer
EP3752198A4 (fr) Émetteur d'électrons thérapeutiques pour le traitement du cancer
EP3877514A4 (fr) Compositions et procédés pour le traitement du cancer
MA51615A (fr) Polytherapie pour le traitement ou la prévention du cancer